Since our first Canadian International Consensus meeting in 2003 when plasma-derived C1-inhibitor concentrates had been available for decades in Europe but not widely outside Europe, many new therapies have emerged in HAE management. This evidence concerns the gene SERPING1 and hereditary angioedema.